Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race

被引:101
作者
Magee, MH
Blum, RA
Lates, CD
Jusko, WJ [1 ]
机构
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[2] Millard Fillmore Hosp, Clin Pharmacokinet Lab, Kaleida Hlth, Buffalo, NY 14209 USA
关键词
D O I
10.1177/00912700122012733
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prednisolone pharmacokinetics (PK) and pharmacodynamics (PD) were investigated in relation to sex and race in white males, black males, white females, and black females (n = 8/group) after a single oral dose (0.27 mg/kg) of prednisone. The study consisted of baseline and prednisone phases with 32-hour sampling in each phase. Women were studied during the luteal phase of their menstrual cycle. Total and free plasma prednisolone concentrations were assayed by HPLC and ultrafiltration, and pharmacokinetic data were analyzed by compartmental fitting using WinNonlin. Plasma cortisol concentrations were assayed by HPLC; T-helper, T-suppressor lymphocyte, and neutrophil cell counts were determined by FACS and hemocytometry, and these pharmacodynamic data were evaluated by basic and extended indirect response models using ADAPT II. Total body weight-normalized free prednisolone oral clearance and apparent volume of distribution were higher in men compared with women, regardless of race (by 22% in whites and 40% in blacks for oral clearance, p < 0.01; by 32% in whites and 38% in blacks for apparent volume of distribution, p < 0.01). The 50% inhibitory concentration (IC50) values for T-suppressor cell-trafficking inhibition were higher in whites than in blacks, regardless of sex (by 125% in men and 208% in women, p < 0.01). The IC50 or SC50 values for effects of prednisolone on cortisol secretion and T-helper lymphocyte or neutrophil trafficking were not statistically different between men and women, blacks and whites. The findings of this study suggest that there are some prednisolone PK/PD differences related to sex and race. However, these differences do not suggest the need for dosage adjustments, and additional experiments with repeat dosing are needed to fully evaluate the clinical implication of these findings.
引用
收藏
页码:1180 / 1194
页数:15
相关论文
共 46 条
[21]   INCREASED PGE(2) FROM HUMAN MONOCYTES ISOLATED IN THE LUTEAL-PHASE OF THE MENSTRUAL-CYCLE - IMPLICATIONS FOR IMMUNITY [J].
LESLIE, CA ;
DUBEY, DP .
PROSTAGLANDINS, 1994, 47 (01) :41-54
[22]   GENDER-BASED EFFECTS ON METHYLPREDNISOLONE PHARMACOKINETICS AND PHARMACODYNAMICS [J].
LEW, KH ;
LUDWIG, EA ;
MILAD, MA ;
DONOVAN, K ;
MIDDLETON, E ;
FERRY, JJ ;
JUSKO, WJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (04) :402-414
[23]   FEMALE GENDER AS A RISK FACTOR FOR TORSADES-DE-POINTES ASSOCIATED WITH CARDIOVASCULAR DRUGS [J].
MAKKAR, RR ;
FROMM, BS ;
STEINMAN, RT ;
MEISSNER, MD ;
LEHMANN, MH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (21) :2590-2597
[24]   CYCLIC VARIATIONS IN WHITE CELL SUB-POPULATIONS IN THE HUMAN MENSTRUAL-CYCLE - CORRELATIONS WITH PROGESTERONE AND ESTRADIOL [J].
MATHUR, S ;
MATHUR, RS ;
GOUST, JM ;
WILLIAMSON, HO ;
FUDENBERG, HH .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1979, 13 (03) :246-253
[25]   ALTERATIONS IN PREDNISOLONE DISPOSITION AS A RESULT OF TIME OF ADMINISTRATION, GENDER AND DOSE [J].
MEFFIN, PJ ;
BROOKS, PM ;
SALLUSTIO, BC .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (04) :395-404
[26]   PHARMACODYNAMIC MODEL FOR JOINT EXOGENOUS AND ENDOGENOUS CORTICOSTEROID SUPPRESSION OF LYMPHOCYTE TRAFFICKING [J].
MILAD, MA ;
LUDWIG, EA ;
ANNE, S ;
MIDDLETON, E ;
JUSKO, WJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1994, 22 (06) :469-480
[27]  
MIYAWAKI T, 1984, CLIN EXP IMMUNOL, V55, P618
[28]   DIURNAL SLEEP WAKE-RELATED IMMUNE FUNCTIONS DURING THE MENSTRUAL-CYCLE OF HEALTHY-YOUNG WOMEN [J].
MOLDOFSKY, H ;
LUE, FA ;
SHAHAL, B ;
JIANG, CG ;
GORCZYNSKI, RM .
JOURNAL OF SLEEP RESEARCH, 1995, 4 (03) :150-159
[29]  
Nakayama A, 1999, BIOL PHARM BULL, V22, P535
[30]   Immunosuppressive therapy in high-risk transplant patients - Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients [J].
Neylan, JF .
TRANSPLANTATION, 1997, 64 (09) :1277-1282